The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport
Abstract
Several lines of emerging evidence indicate that kidney disease differentially affects uptake and efflux transporters and metabolic enzymes in the liver and gastrointestinal (GI) tract, and uremic toxins have been implicated as the cause. In patients with kidney disease, even drugs that are eliminated by nonrenal transport and metabolism could lead to important unintended consequences if they are administered without dose adjustment for reduced renal function. This is particularly so in the case of drugs with narrow therapeutic windows and may translate into clinically significant variations in exposure and response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Effects of renal failure on drug transport and metabolism
Sun, H., Frassetto, L., & Benet, L. Z. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.010 · Cited by 290
Downregulation of Hepatic Cytochrome P450 in Chronic Renal Failure
LEBLOND, F., GUÉVIN, C., DEMERS, C., PELLERIN, I., GASCON-BARRÉ, M., & PICHETTE, V. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v122326 · Cited by 213
Self-citationCyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
Haubitz, M., Bohnenstengel, F., Brunkhorst, R., Schwab, M., Hofmann, U., & Busse, D. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00279.x · Cited by 177
EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
Sun, H. L., Huang, Y., Frassetto, L. A., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000521 · Cited by 128
Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats
Naud, J., Michaud, J., Boisvert, C., Desbiens, K., Leblond, F. A., Mitchell, A., Jones, C., Bonnardeaux, A., & Pichette, V. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112631 · Cited by 126
Self-citationHemodialysis Acutely Improves Hepatic CYP3A4 Metabolic Activity
Nolin, T. D., Appiah, K. K., Kendrick, S. A., Le, P. T., McMonagle, E., & Himmelfarb, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060610 · Cited by 126
Self-citationCharacterization of hepatic cytochrome P4503A activity in patients with end‐stage renal disease
Dowling, T. C., Briglia, A., Fink, J. C., Hanes, D. S., Light, P. D., Stackiewicz, L., Karyekar, C. S., Eddington, N. D., Weir, M. R., & Henrich, W. L. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00056-0 · Cited by 122
Cited by
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
Verbeeck, R. K., & Musuamba, F. T. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0678-8 · Cited by 717
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Matzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K.-U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., et al. (2011) · Kidney International · doi:10.1038/ki.2011.322 · Cited by 462
Jamei, M., Dickinson, G. L., & Rostami-Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 368
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0440-1 · Cited by 206
“Based on the low urinary excretion of afatinib-related radioactivity (\5 %) found in the ADME study [40], the renal impairment study [39] and the PopPK analysis [35], it may be hypothesized that non-renal elimination pathways of afatinib are impacted by renal function, such as a decrease in expression and/or activity…”
Background
Metadata
- Authors
- Nolin, T., Naud, J., Leblond, F., & Pichette, V
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2008-04-02
- Volume
- 83
- Issue
- 6
- Pages
- 898-903
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2050094658
- Cited by
- 276
- References
- 23
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport. https://app.cochat.ai/papers/10.1038/clpt.2008.59
- The paper
- Nolin, T., Naud, J., Leblond, F., & Pichette, V. (2008). Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2008.59
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.